ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Vascular Response to Isoproterenol and β2 Adrenergic Receptor Polymorphisms

This study has been completed.

Sponsored by: Hadassah Medical Organization
Information provided by: Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00226551
  Purpose

Single nucleotide polymorphisms at codon 46 and 79 of the gene encoding for the ß2 adrenergic receptor (ß2AR) modify its pharmacological properties and may alter the response to ß2AR agonists. The goal of the present study was to evaluate the role played by the Arg16Gly and Gln27Glu polymorphisms on isoproterenol induced relaxation of internal mammary arteries segments ex-vivo.

Internal mammary leftover segments were collected from 96 patients undergoing coronary artery bypass graft operation. Four rings that were prepared from each specimen were allowed to reach equilibrium with physiological Krebs solution prior to precontraction with U46619. Using the organ bath technique, cumulative dose response curve of isoproterenol was constructed and mean EC50 calculated for each patient.


Condition Intervention
Coronary Disease
Drug: Isoproterenol

ChemIDplus related topics:   Isoproterenol    Isoproterenol hydrochloride    Isoproterenol sulfate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Other, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacodynamics Study
Official Title:   ß2 Adrenergic Receptor Polymorphisms and Vasodilation of Internal Mammary Artery Induced by Isoproterenol

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • Mean Ec50% in response to rising concentration of isoproterenol

Estimated Enrollment:   100
Study Start Date:   August 1999

  Eligibility
Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • patients scheduled to undergo coronary artery bypass graft operation

Exclusion Criteria:

  • Chronic treatment with corticosteroids
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00226551

Locations
Israel
Hadassah Medical Organization    
      Jerusalem, Israel

Sponsors and Collaborators
Hadassah Medical Organization

Investigators
Principal Investigator:     Yoseph Caraco, MD     Hadassah Medical Organization    
  More Information


Publications indexed to this study:

Study ID Numbers:   yc19558-HMO-CTIL
First Received:   September 12, 2005
Last Updated:   March 17, 2008
ClinicalTrials.gov Identifier:   NCT00226551
Health Authority:   Israel: Israeli Health Ministry Pharmaceutical Administration

Study placed in the following topic categories:
Coronary Disease
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Ischemia
Isoproterenol

Additional relevant MeSH terms:
Respiratory System Agents
Neurotransmitter Agents
Adrenergic beta-Agonists
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Sympathomimetics
Cardiotonic Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Cardiovascular Agents
Protective Agents
Adrenergic Agonists
Pharmacologic Actions
Autonomic Agents
Therapeutic Uses
Cardiovascular Diseases
Peripheral Nervous System Agents
Bronchodilator Agents

ClinicalTrials.gov processed this record on October 10, 2008




Links to all studies - primarily for crawlers